Aytu bioscience announces close of merger with neos therapeutics

$100m revenue specialty pharmaceutical company on an accelerated path to profitability[1] company name change to aytu biopharma, inc. becomes effective today former neos therapeutics board members beth p. hecht and gerald mclaughlin have joined the aytu biopharma board of directors englewood, co / accesswire / march 22, 2021 / aytu bioscience, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today announced the closing of its merger with neos therapeutics (previously trading on nasdaq under "neos").
AYTU Ratings Summary
AYTU Quant Ranking